Research interests
Department of Defense-funded IND-enabling studies for an RNA therapeutic to treat atherosclerosis[4]
2024 to 2029
LZ
Lisheng Zhang
Resident at Xinjiang Medicine University (China)
As of 1994 · Last known relationship
Resident at Xinjiang Medicine University (China)
As of 1994 · Last known relationship
Lisheng Zhang is an Associate Professor in Medicine at Duke University whose research investigates inflammatory signaling and cellular remodeling in vein-graft disease and atherosclerosis. He developed and characterized mouse interposition vein-graft and arterial-wall transplantation models to study which cells and gene products contribute to vascular pathology. His publications address USP20 and IRAK1-linked IL-1β signaling, TNF receptor-1, drebrin, interleukin-9, and vascular smooth muscle cells. Zhang earned an M.D. from Nanjing Medical University in 1988 and completed residency at Xinjiang Medicine University from 1988 to 1994. His profile lists earlier Duke appointments as Assistant Professor in Medicine and Visiting Scholar of Medicine. Listed research support includes vascular homeostasis, small nucleolar RNAs in atherosclerosis, and an RNA therapeutic.
Each topic is linked to its supporting source in Sources.
Training includes Resident at Xinjiang Medicine University (China), M.D. from Nanjing Medical University (China), Past Visiting Scholar of Medicine at Duke University, and Associate Professor in Medicine at Duke University, plus 1 more record.
Explore education and trainingDepartment of Defense-funded IND-enabling studies for an RNA therapeutic to treat atherosclerosis[4]
2024 to 2029
Development and characterization of an interposition vein graft model in mice[4]
NHLBI-funded research on mechanisms by which small nucleolar RNAs exacerbate atherosclerosis[4]
2022 to 2026
NIH-funded research on mechanisms regulating vascular homeostasis[4]
2021 to 2026
Publication: Angiotensin II-Induced Aortic Inflammation and Remodeling Are Mitigated by the Actin-Binding Protein Drebrin (2017)[4]
From 2017
Publication: Drebrin attenuates atherosclerosis by limiting smooth muscle cell transdifferentiation (2022)[4]
From 2022
Publication: Drebrin regulates angiotensin II-induced aortic remodelling (2018)[4]
From 2018
Publication: Interleukin-9 mediates chronic kidney disease-dependent vein graft disease: a role for mast cells (2017)[4]
From 2017
Publication: Phosphorylation of USP20 on Ser334 by IRAK1 promotes IL-1β-evoked signaling in vascular smooth muscle cells and vascular inflammation (2023)[4]
From 2023
Publication: The Actin-Binding Protein Drebrin Inhibits Neointimal Hyperplasia (2016)[4]
From 2016
Publication: The Atherosclerosis Candidate Gene Product Kalirin Reduces Atherosclerosis via Macrophage-Specific Mechanisms (2017)[4]
From 2017
Publication: The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model (2026)[4]
From 2026
Publication: Ubiquitin-Specific Protease 20 Attenuates Atherosclerosis through Activity in Smooth Muscle Cells (2016)[4]
From 2016
Publication: USP20 (Ubiquitin-Specific Protease 20) Inhibits TNF (Tumor Necrosis Factor)-Triggered Smooth Muscle Cell Inflammation and Attenuates Atherosclerosis (2018)[4]
From 2018
Research on the pathogenesis of vein graft neointimal hyperplasia and atherosclerosis[4]
Studies of inflammatory cytokine receptors in neointimal hyperplasia and atherosclerosis[4]